Obesidad y disfunción cardiorrenal: el impacto de la inflamación y la lipotoxicidad
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Rico Fontalvo, Jorge | |
| dc.contributor.author | Daza Arnedo, Rodrigo | |
| dc.contributor.author | Raad Sarabia, Maria | |
| dc.contributor.author | Montejo Hernández, Juan | |
| dc.contributor.author | Rodríguez Yánez, Tomas | |
| dc.contributor.author | Jiménez Quintero, Javier | |
| dc.contributor.author | González Arias, Mauricio | |
| dc.contributor.author | Araiza Garaygordobil, Diego | |
| dc.date.accessioned | 2026-02-02T16:32:21Z | |
| dc.date.available | 2026-02-02T16:32:21Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | La obesidad es una enfermedad sistémica poco reconocida durante años. La enfermedad renal crónica asociada a obesidad (ERC-Ob) es un trastorno multifacético que afecta a pacientes con obesidad en diversos grados. Esta situación se da por mecanismos directos e indirectos y estos pacientes tienen riesgo aumentado de desarrollar enfermedad cardiovascular (ECV) con sus diferentes manifestaciones, incluyendo enfermedad arterial coronaria, insuficiencia cardíaca (IC) o arritmias y muerte súbita cardiaca. Hay una interacción compleja entre obesidad, enfermedad renal crónica (ERC) y el desarrollo de compromiso cardiaco. En los últimos años, se ha incrementado el interés por comprender el papel de la obesidad en el desarrollo de ERC y falla cardíaca | spa |
| dc.description.abstract | Obesity is a systemic disease that has been underrecognized for years. Obesity-associated chronic kidney disease (Ob-CKD) is a multifaceted disorder affecting patients with varying degrees of obesity. This condition arises through both direct and indirect mechanisms, and these patients have an increased risk of developing cardiovascular disease (CVD) with its different manifestations, including coronary artery disease, heart failure (HF), arrhythmias, and sudden cardiac death. There is a complex interaction between obesity, chronic kidney disease (CKD), and the development of cardiac involvement. In recent years, there has been increasing interest in understanding the role of obesity in the development of CKD and heart f failure. | eng |
| dc.format.mimetype | ||
| dc.identifier.citation | Rico Fontalvo J, Daza Arnedo R, Raad Sarabia M, Montejo Hernández J, Rodríguez Yánez T, Jiménez Quintero J, González Arias M, Araiza Garaygordobil D. Obesidad y disfunción cardiorrenal: el impacto de la inflamación y la lipotoxicidad. Rev. Colomb. Nefrol. [Internet]. 30 de enero de 2026 [citado 2 de febrero de 2026];13(1). Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/1071 | |
| dc.identifier.doi | http://doi.org/10.22265/acnef.13.1.1071 | |
| dc.identifier.issn | 2500-5006 (Electrónico) | |
| dc.identifier.issn | 2389-7708 (Impreso) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/17319 | |
| dc.identifier.url | https://revistanefrologia.org/index.php/rcn/article/view/1071 | |
| dc.language.iso | spa | |
| dc.publisher | Asociación Colombiana de Nefrología e Hipertensión Arterial | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Revista Colombiana de Nefrología | spa |
| dc.source | Vol. 13 No. 1 Año 2026 | spa |
| dc.subject | Inflamación | spa |
| dc.subject | Lipotoxicidad | spa |
| dc.subject | Citoquinas | spa |
| dc.subject | Obesidad | spa |
| dc.subject | Enfermedad renal crónica | spa |
| dc.subject | Enfermedad cardiovascular | spa |
| dc.subject.keywords | Inflammation | eng |
| dc.subject.keywords | lipotoxicity | eng |
| dc.subject.keywords | cytokines | eng |
| dc.subject.keywords | chronic kidney disease | eng |
| dc.subject.keywords | cardiovascular disease | eng |
| dc.subject.keywords | obesity | eng |
| dc.title | Obesidad y disfunción cardiorrenal: el impacto de la inflamación y la lipotoxicidad | spa |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Nawaz S, Chinnadurai R, Al-Chalabi S, Evans P, Kalra PA, Syed AA, et al. Obesity and chronic kidney disease: a current review. Obes Sci Pract. 2022;9(2):61-74. https://doi.org/10. 1002/osp4.629 ↑Ver página 3, 7 | eng |
| dcterms.references | Lu JL, Kalantar-Zadeh K, Ma JZ, Quarles LD, Kovesdy CP. Association of body mass index with outcomes in patients with CKD. J Am Soc Nephrol. 2014;25(9):2088-96. https://doi.org/ 10.1681/asn.2013070754 ↑Ver página 3 | eng |
| dcterms.references | Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney Int Suppl. 2017;7(2):122-9. https://doi.org/10.1016/j.kisu.2017.07.007 ↑Ver página 3 | eng |
| dcterms.references | Hojs R, Ekart R, Bevc S, Vodošek Hojs N. Chronic kidney disease and obesity. Nephron. 2023;147(11):660-4. https://doi.org/10.1159/000531379 ↑Ver página 3 | eng |
| dcterms.references | Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157-72. https://doi.org/10.1161/circulationaha.120.050686 ↑Ver página 3 | eng |
| dcterms.references | Schuett K, Marx N, Lehrke M. The cardio-kidney patient: epidemiology, clinical characteristics and therapy. Circ Res. 2023;132(8):902-14. https://doi.org/10.1161/circresaha.122. 321748 ↑Ver página 3 | eng |
| dcterms.references | Chen X, Ruiz-Velasco A, Zou Z, Hille SS, Ross C, Fonseka O, et al. PAK3 exacerbates cardiac lipotoxicity via SREBP1c in obesity cardiomyopathy. Diabetes. 2024;73(11):1805-20. https:// doi.org/10.2337/db24-0240 ↑Ver página 3, 10 | eng |
| dcterms.references | Solomon SD, Ostrominski JW, Wang X, Shah SJ, Borlaug BA, Butler J, et al. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. J Am Coll Cardiol. 2024;84(17):1587-602. https://doi.org/10.1016/j.jacc.2024.08.021 ↑Ver página 3 | eng |
| dcterms.references | Cases A, Broseta JJ, Marqués M, Cigarrán S, Julián JC, Alcázar R, et al. La definición del síndrome cardiovascular-reno-metabólico (cardiovascular-kidney-metabolic syndrome) y su papel en la prevención, estatificación del riesgo y tratamiento. Una oportunidad para la Nefrología. Nefrología. 2024;44(6):769-920. https://www.revistanefrologia.com/ es-la-definicion-del-sindrome-cardiovascular-reno-metabolico-articulo-S0211699524000365 ↑Ver página 4, 11 | spa |
| dcterms.references | Rico-Fontalvo J, Daza-Arnedo R, Montejo-Hernandez J, Cardona-Blanco M, RodríguezYanez T. Reflexiones de la enfermedad renal crónica asociada a obesidad: de una vieja relación causal hasta un enfoque basado en la fenotipificación. Rev Soc Ecuat Nefrol Diálisis Traspl. 2022;10(2):137-9. https://doi.org/10.56867/37 ↑Ver página 4 | spa |
| dcterms.references | León-Román J, López-Martínez M, Esteves A, Ciudin A, Núñez-Delgado S, Álvarez T, et al. Obesity-related kidney disease: a growing threat to renal health. Int J Mol Sci. 2025;26(14):6641. https://doi.org/10.3390/ijms26146641 ↑Ver página 4, 9 | eng |
| dcterms.references | Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625-33. https://doi.org/10.1161/01.hyp.0000052314.95497.78 ↑Ver página 5 | eng |
| dcterms.references | Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498-509. https://doi.org/10.1046/ j.1523-1755.2001.0590041498.x ↑Ver página 5, 8, 9 | eng |
| dcterms.references | Martin-Taboada M, Vila-Bedmar R, Medina-Gómez G. From obesity to chronic kidney disease: how can adipose tissue affect renal function? Nephron. 2021;145(6):609-13. https:// doi.org/10.1159/000515418 ↑Ver página 5 | eng |
| dcterms.references | Tobar A, Ori Y, Benchetrit S, Milo G, Herman-Edelstein M, Zingerman B, et al. Proximal tubular hypertrophy and enlarged glomerular and proximal tubular urinary space in obese subjects with proteinuria. PloS One. 2013;8(9):e75547. https://doi.org/10.1371/journal.pone. 0075547 ↑Ver página 5 | eng |
| dcterms.references | Chen Y, Dabbas W, Gangemi A, Benedetti E, Lash J, Finn PW, et al. Obesity management and chronic kidney disease. Semin Nephrol. 2021;41(4):392-402. https://doi.org/10.1016/ j.semnephrol.2021.06.010 ↑Ver página 5 | eng |
| dcterms.references | Sweiss N, Sharma K. Adiponectin effects on the kidney. Best Pract Res Clin Endocrinol Metab. 2014;28(1):71-9. https://doi.org/10.1016/j.beem.2013.08.002 ↑Ver página 5 | eng |
| dcterms.references | Rico-Fontalvo J, Ciudin A, Correa-Rotter R, Díaz-Crespo FJ, Bonanno C, Lecube A, et al. SEN, SLANH, and SEEDO Consensus report on Obesity related kidney disease. Proposal for a new classification. Kidney Int. 2025;108(4):572-83. https://doi.org/10.1016/j.kint.2025.06.013 ↑Ver página 6 | eng |
| dcterms.references | Ren L, Cui H, Wang Y, Ju F, Cai Y, Gang X, et al. The role of lipotoxicity in kidney disease: From molecular mechanisms to therapeutic prospects. Biomed Pharmacother. 2023;161:114465. https://doi.org/10.1016/j.biopha.2023.114465 ↑Ver página 6, 8 | eng |
| dcterms.references | Rico-Fontalvo J, Daza-Arnedo R, Rodriguez-Yanez T, Martinez-Avila MC, Cabrales J, Cardona-Blanco MX, et al. Inflammation and diabetic kidney disease: new perspectives. J Biomed Res Environ Sci. 2022;3(7):779-86. https://doi.org/10.37871/jbres1513 ↑Ver página 7, 8 | eng |
| dcterms.references | Zhu Q, Scherer PE. Immunologic and endocrine functions of adipose tissue: implications for kidney disease. Nat Rev Nephrol. 2018;14(2):105-20. https://doi.org/10.1038/nrneph.2017. 157 ↑Ver página 7 | eng |
| dcterms.references | Schelling JR. The contribution of lipotoxicity to diabetic kidney disease. Cells. 2022;11(20):3236. https://doi.org/10.3390/cells11203236 ↑Ver página 7 | eng |
| dcterms.references | Garbarino J, Sturley SL. Saturated with fat: new perspectives on lipotoxicity. Curr Opin Clin Nutr Metab Care. 2009;12(2):110-6. https://doi.org/10.1097/mco.0b013e32832182ee ↑Ver página 9 | eng |
| dcterms.references | Zbrzeźniak-Suszczewicz J, Winiarska A, Perkowska-Ptasińska A, Stompór T. Obesity-related glomerulosclerosis—how adiposity damages the kidneys. Int J Mol Sci. 2025;26(13):6247. https://doi.org/10.3390/ijms26136247 ↑Ver página 9 | eng |
| dcterms.references | Fazeli SA, Nourollahi S, Alirezaei A, Mirhashemi S, Davarian A, Hosseini I. Perirenal adipose tissue: clinical implication and therapeutic interventions. Indian J Nephrol. 2024;34(6):573-82. https://doi.org/10.25259/ijn 532 23 ↑Ver página 9 | eng |
| dcterms.references | D’Marco L, Salazar J, Cortez M, Salazar M, Wettel M, Lima-Martínez M, et al. Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease. Kidney Res Clin Pract. 2019;38(3):365-72. https://doi.org/10.23876/j.krcp.18.0155 ↑Ver página 9 | eng |
| dcterms.references | Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380(1-2):24-30. https://doi.org/10.1016/j.cca.2007.01.026 ↑Ver página 9 | eng |
| dcterms.references | Vilariño-García T, Polonio-González ML, Pérez-Pérez A, Ribalta J, Arrieta F, Aguilar M, et al. Role of leptin in obesity, cardiovascular disease, and type 2 diabetes. Int J Mol Sci. 2024;25(4):2338. https://doi.org/10.3390/ijms25042338 ↑Ver página 9 | eng |
| dcterms.references | Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation. Circ Res. 2020;126(6):789-806. https://doi.org/10.1161/circresaha.119.312321 ↑Ver página 10 | eng |
| dcterms.references | Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606-35. https://doi.org/10.1161/cir.0000000000001184 ↑Ver página 10, 11 | eng |
| dcterms.references | Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025;31(2):544-51. https://doi.org/10.1038/s41591-024-03374-z ↑Ver página 10 | eng |
| dcterms.references | Kadowaki T, Maegawa H, Watada H, Yabe D, Node K, Murohara T, et al. Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan. Diabetes Obes Metab. 2022;24(12):2283-96. https://doi.org/10.1111/dom.14829 ↑Ver página 10 | eng |
| dcterms.references | Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137-88. https://doi.org/10.1152/physrev.00045.2011 ↑Ver página 10 | eng |
| dcterms.references | Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144-53. https://doi.org/10.1038/nrendo.2015. 216 ↑Ver página 10 | eng |
| dcterms.references | Packer M, Zile MR, Kramer CM, Murakami M, Ou Y, Borlaug BA, et al. Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial. J Am Coll Cardiol. 2025;85(18):1721-35. https://doi. org/10.1016/j.jacc.2025.03.009 ↑Ver página 11 | eng |
| dcterms.references | Chen Y, Wu S, Liu H, Zhong Z, Bucci T, Wang Y, et al. Role of oxidative balance score in staging and mortality risk of cardiovascular-kidney-metabolic syndrome: Insights from https://revistanefrologia.org http://www.asocolnef.com Obesidad y disfuncion cardiorrenal ´ 17 traditional and machine learning approaches. Redox Biol. 2025;81:103588. https://doi.org/ 10.1016/j.redox.2025.103588 ↑Ver página 11 | eng |
| dcterms.references | Boorsma EM, Ter Maaten JM, Damman K, van Essen BJ, Zannad F, van Veldhuisen DJ, et al. Albuminuria as a marker of systemic congestion in patients with heart failure. Eur Heart J. 2023;44(5):368-80. https://doi.org/10.1093/eurheartj/ehac528 ↑Ver página 11 | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |